Peripheral Nerve Injury
Conditions
Interventions
Experimental group:1) Basic treatment: Oral administration of Methylcobalamin tablets (Weizai Pharmaceutical Co., Ltd., National Drug Approval No. H20143107) 0.5mg, three times daily, with a four-week
Control group:Basic treatment: Oral administration of Methylcobalamin tablets (Weizai Pharmaceutical Co., Ltd., National Drug Approval No. H20143107) 0.5mg, three times daily, with a four-week course
Sponsors
Jiangsu Province Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1) Pathologically or cytologically confirmed malignant tumours treated with chemotherapy agents possessing potential peripheral neurotoxicity. 2) Aged 18 to 85 years, male or female. 3) Peripheral neurotoxicity grade = Grade I. 4) Karnofsky Performance Status (KPS) = 60 points, with a projected survival period exceeding 3 months, and normal cardiac, hepatic, and renal function.
Exclusion criteria
Exclusion criteria: 1) Peripheral neuropathy caused by other factors, such as diabetes, infection, or poisoning; or patients with pre-existing peripheral sensory abnormalities, neurological disorders, or those currently receiving other neurotoxic medications. 2) Pregnant or breastfeeding women. 3) Patients with psychiatric disorders or impaired consciousness who are unable to cooperate with assessment. 4) Patients with severe skin conditions or skin lesions on the extremities.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Traditional Chinese Medicine Syndrome Scoring;Brief Pain Inventory ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Electromyogram ; | — |
Countries
China
Contacts
Public ContactHai-yang Fu
Jiangsu Province Hospital of Chinese Medicine
Outcome results
None listed